

For Immediate Release

**Alembic Pharmaceuticals Ltd.
Consolidated Results for quarter ended 30.09.2012**

**Revenues up 2% at Rs 408 crores against Rs. 398 crores in PY
PBT up 18% at Rs 52.98 crores against Rs. 45.04 crores in PY
3 ANDA approvals received in last fortnight**

Editors Synopsis

Quarter ended 30th September, 2012

- **Net sales up 2% at Rs 408 crores for the quarter against Rs. 398 crores in corresponding quarter last year**
- **Domestic formulations sales up 12% for the quarter at Rs. 254 crores against Rs. 227 crores in corresponding quarter last year**
- **EBITDA at 15.9% at Rs. 64.70 crores**
- **Profit before tax up 18% at 52.98 crores against Rs. 45.04 crores in corresponding quarter last year**
- **Net profit after tax up 12% for the quarter at Rs. 42.49 crores vis-à-vis Rs. 38.04 crores in P.Y.**
- **Net sales up 4% for H1 at Rs.776 crores against Rs.743 crores for corresponding H1 last year**
- **PBT up 12% for H1 at Rs. 91 crores against Rs. 81 crores for corresponding H1 last year**
- **One ANDA filing during the quarter. Cumulative filing stands at 50**

Vadodara, 19th October, 2012

Alembic Pharmaceuticals Limited reported a 2% increase in revenues to Rs 407.53 crores for the quarter ended 30th September 2012, compared to Rs 398.05 crores in the corresponding quarter last year.

The Company posted 18% growth in profit before tax at Rs. 52.98 crores for the quarter ended 30th September 2012 against Rs 45.04 crores posted in corresponding quarter last fiscal.

The net profit grew by 12% at Rs. 42.49 crores for the quarter ended 30th September 2012 against Rs. 38.04 crores in corresponding quarter last fiscal.

The company also reported 4% increase in revenue for first half of operations to Rs. 775.59 crores against Rs. 742.77 crores corresponding first half last year.

The company also posted 12% growth in profit before tax at Rs. 91.08 crores for first half against Rs. 80.51 crores for corresponding first half last year. The Company also reported 12% growth in net profit for first half at Rs. 73.33 crores against Rs. 65.60 crores in corresponding first half last year.

EBIDTA margins for quarter ended September 12 up at 15.9% to Rs. 64.70 crores from 15.2% for corresponding quarter last year.

Domestic Formulations Business

The Domestic formulations business posted sales of Rs. 253.87 crores against Rs. 226.92 crores with a 12% growth over the corresponding quarter of the previous year.

Alembic maintained market share of 1.74%

Alembic has four brands in the list of top 300 brands of industry i.e. 'Azithral', 'Roxid', 'Althrocin' and 'Wikoryl'.

Some of the specialty segments which the company entered recently are showing good progress.

The company launched a dermatology division in current year which is showing encouraging result in first two quarters of operations. This will further add to the basket of specialty products and growth in the future.

API

For the quarter, Export API recorded sales of Rs. 57.60 crores against Rs. 60.44 crores while domestic API recorded sales of Rs. 33.35 crores against Rs. 22.01 crores in corresponding quarter last year.

International Generics

International Generic Formulation sales is Rs. 51.01 crores against Rs. 71.38 crores over the corresponding quarter last year. De-growth was in line with our expectations due to price erosion, product mix and capacity constraint.

During the quarter 1 ANDA application was filed taking cumulative ANDA filings of the Company to 50. Cumulative ANDA approvals now stands at 21.

Summary of total revenue (consolidated) for the quarter is as under:

(Rs. in Lacs)

Particulars			
	Q2 FY13	Q2 FY12	% Change
Formulation			
Domestic	25387	22692	12%
International Branded	868	1204	(-)28%
International Generics	5101	7138	(-)29%
API			
Domestic	3335	2201	52%
International	5760	6044	(-)5%
Export incentives	302	526	(-)43%
Total	40753	39805	2%

The Profit break-up for the quarter is as under:

(Rs. in Lacs)

Particulars	Q2 FY13	Q2 FY12	% Change
Operating Income	6470	6047	7%
Profit Before Tax	5298	4504	18%
Net Profit after Tax	4249	3804	12%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 3000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information:

Mitanshu Shah

Phone: +91 265 – 3007630

Email: mitanshu.shah@alembic.co.in

Alembic Pharmaceuticals Limited